Navigation Links
Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
Date:10/16/2007

Agreement with Kaketsuken targets rare blood disorders

DEERFIELD, Ill., Oct. 16 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) today announced it has signed an agreement with Kaketsuken, the Chemo-Sero-Therapeutic Research Institute, based in Kumamoto Japan, for the worldwide rights to develop, manufacture and market the recombinant protein ADAMTS13. The development of recombinant ADAMTS13, a bio-engineered version of a naturally occurring enzyme that plays a critical role in blood coagulation, will strengthen Baxter's pre-clinical research and development pipeline for specialty therapeutics targeting rare diseases. In the absence of ADAMTS13 in the blood, patients develop a severe, often life-threatening condition called thrombotic thrombocytopenic purpura (TTP), marked by the formation of platelet-rich blood clots in blood vessels throughout the body. Recombinant ADAMTS13 is being developed for the treatment of TTP and related disorders and will be evaluated for other indications in the future. This agreement provides an opportunity for Baxter to exclusively develop a new recombinant protein and investigate its potential use in treating unmet medical needs.

"We are very excited to add recombinant ADAMTS13 to our development pipeline," said Hartmut J. Ehrlich, M.D., vice president of Global Research and Development for Baxter's BioScience business. "Elucidating the role of recombinant ADAMTS13 in TTP and other blood-clotting disorders might provide us with a new treatment modality for thrombotic diseases, which is a substantial addition to our R&D pipeline."

When a blood vessel is injured, a platelet plug is formed that adheres to the injury site and reduces or stops the blee
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expression and Purification of Recombinant Proteins That Have Native Amino Acid Sequence
2. Proteinase K, Recombinant, PCR Grade: the Ideal Tool for Template Preparations
3. Recombinant HIV Reverse Transcriptase
4. Purification of Recombinant Flavonone 3beta-Hydroxylase Using Bio-Scale CHT5-1 Hydroxyapatite Column
5. Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C
6. Cell lines expressing recombinant aequorin and a G-protein coupled receptor for functional screening
7. Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38)
8. A New C-Terminal GST Vector for Protein Production in S. pombe
9. New Mammalian Two-Hybrid System Detects Protein-Protein Interactions
10. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
11. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... -- Spectrum Equity Investors of Boston will become the ... national provider of technology to mortgage lenders. , , ... an $84 million recapitalization of Mortgagebot. , ,Following the ... join Mortgagebot's board of directors. Terms of the transaction ...
... -- Metavante Corp., the financial technology subsidiary of Marshall ... of Nashville, Tenn., The company will continue to operate ... subsidiary of Metavante , with existing management continuing ... the transaction were not disclosed. , ,LINK2GOV provides ...
... The WiCell Research Institute's announcement Monday that it has ... to create the nation's first National Stem Cell Bank ... and innovative approach to the new field of research. ... opposition to embryonic stem cell research, the path forward ...
Cached Biology Technology:Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot 2Metavante acquiring LINK2Gov 2WiCell to host new national stem cell bank 2WiCell to host new national stem cell bank 3WiCell to host new national stem cell bank 4
(Date:7/9/2014)... of a sparrow-sized fossil from China challenges the commonly ... that gained the ability to fly. The birdlike fossil ... much rather the remains of a tiny tree-climbing animal ... the Dinosaur Museum in Blanding, Utah, and Alan Feduccia ... in Springer,s Journal of Ornithology . , The ...
(Date:7/9/2014)... by researchers at the NIH,s National Center ... collaborators to treat sickle cell disease has ... The drug candidate, Aes-103, is the first ... mechanism of sickle cell disease. Baxter now ... for regulatory approval and commercialization. , Sickle ...
(Date:7/9/2014)... inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate ... to affect irreversible cognitive dysfunction and effectively ... Amyloid beta peptide (Aβ) vaccines reduced and ... (AD) transgenic mouse model, and significantly improved ... and his team, First Affiliated Hospital of ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2010.   Revenues for the third quarter of ... million in the same quarter last year. Net income for the ... These results compared to a net loss of $1.1 million, or ...
... BOSTON The discovery that a protein called Rictor plays ... AKT oncogene could provide scientists with a new molecular target ... September 2010 issue of the journal Molecular Cell , ... Medical Center (BIDMC). The oncogenic cousin, known as ...
... Nanomedicine Center for Nucleoprotein Machines has received an award ... its renewal by the National Institutes of Health (NIH). ... of a clinically viable gene correction technology for single-gene ... disease. Sickle cell disease is a genetic condition ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2010 Financial Results 2Aware, Inc. Reports Third Quarter 2010 Financial Results 3Aware, Inc. Reports Third Quarter 2010 Financial Results 4Aware, Inc. Reports Third Quarter 2010 Financial Results 5Rictor protein offers scientists a new molecular target for cancer therapies 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 3NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 4
... system holds 48 x 0.2 ml tubes, or a ... fluorescence (470-500 nm) for each well, and a pair ... 540-700 nm). This item is a real-time upgrade for ... are 18 x 32 x 33 cm (W x ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... Cellomics KineticScan™ Reader is Cellomics‘ ... Solutions for Cell-based Screening". The ... ability to do both temporal ... physiological processes, dynamic distribution and ...
... PULSin may be superior to transfection in ... transfection, with PULSin you can study lethal ... course of proteins in cells. Likewise, delivery ... than traditional RNA interference experiments. ,With ...
Biology Products: